Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Lancet
    March 2024
  1. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    >> Share

  2. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    >> Share

  3. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

  4. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    >> Share

  5. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    >> Share

  6. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    >> Share

  7. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    >> Share

  8. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    >> Share

  9. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    >> Share

  10. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    >> Share

    February 2024
  11. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    >> Share

  12. THORNTON J
    Reducing patchiness in abortion care in the UK.
    Lancet. 2024 Feb 15:S0140-6736(24)00312-X. doi: 10.1016/S0140-6736(24)00312.
    >> Share

  13. HURRELL A, Webster L, Sparkes J, Battersby C, et al
    Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
    Lancet. 2024 Feb 8:S0140-6736(23)02357-7. doi: 10.1016/S0140-6736(23)02357.
    >> Share

  14. CERDEIRA AS, Karumanchi SA
    Serial placental growth factor-based testing in pre-eclampsia.
    Lancet. 2024 Feb 8:S0140-6736(23)02578-3. doi: 10.1016/S0140-6736(23)02578.
    >> Share

  15. LUCAS N, Rex S, Devroe S
    Treatment modalities for placenta accreta spectrum.
    Lancet. 2024;403:437.
    >> Share

  16. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    Treatment modalities for placenta accreta spectrum - Authors' reply.
    Lancet. 2024;403:437-438.
    >> Share

    January 2024
  17. KAMYA MR, Kakuru A, Dorsey G
    Dihydroartemisinin-piperaquine for prevention of malaria in pregnant women living with HIV.
    Lancet. 2024 Jan 12:S0140-6736(24)00048-5. doi: 10.1016/S0140-6736(24)00048.
    >> Share

  18. BARSOSIO HC, Madanitsa M, Ondieki ED, Dodd J, et al
    Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2024 Jan 12:S0140-6736(23)02631-4. doi: 10.1016/S0140-6736(23)02631.
    >> Share

  19. RIAL-CRESTELO M, Lubusky M, Parra-Cordero M, Krofta L, et al
    Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Jan 11:S0140-6736(23)02228-6. doi: 10.1016/S0140-6736(23)02228.
    >> Share

  20. ELNAKIB S, Fair M, Mayrhofer E, Afifi M, et al
    Pregnant women in Gaza require urgent protection.
    Lancet. 2024 Jan 11:S0140-6736(23)02835-0. doi: 10.1016/S0140-6736(23)02835.
    >> Share

    December 2023
  21. CHAILLET N, Masse B, Grobman WA, Shorten A, et al
    Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.
    Lancet. 2023 Dec 11:S0140-6736(23)01855-X. doi: 10.1016/S0140-6736(23)01855.
    >> Share

  22. OAKNIN A, Gladieff L, Martinez-Garcia J, Villacampa G, et al
    Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Lancet. 2023 Dec 1:S0140-6736(23)02405-4. doi: 10.1016/S0140-6736(23)02405.
    >> Share

  23. MILESHKIN LR, Manoharan S
    Improving survival from metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2023 Dec 1:S0140-6736(23)02690-9. doi: 10.1016/S0140-6736(23)02690.
    >> Share

    November 2023
  24. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    >> Share

  25. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

  26. HOBSON G, Dennis N
    Experiences of menopause in the Welsh NHS workplace: a focus group study.
    Lancet. 2023;402 Suppl 1:S51.
    >> Share

  27. JONG FC, Kotzur M, Amiri R, Ling J, et al
    Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.
    Lancet. 2023;402 Suppl 1:S12.
    >> Share

  28. COWLING A, Nevens L, Contogiorgi N, Bradley N, et al
    Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S35.
    >> Share

    October 2023
  29. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    >> Share

  30. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    >> Share

  31. BHAN N, McDougal L
    Centring agency and norms to meet the health needs of pregnant adolescents.
    Lancet. 2023 Oct 11:S0140-6736(23)02226-2. doi: 10.1016/S0140-6736(23)02226.
    >> Share

  32. SABET F, Prost A, Rahmanian S, Al Qudah H, et al
    The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.
    Lancet. 2023 Oct 11:S0140-6736(23)01682-3. doi: 10.1016/S0140-6736(23)01682.
    >> Share

    August 2023
  33. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    >> Share

  34. JAFFE S
    Abortion foes threaten PEPFAR.
    Lancet. 2023;402:598.
    >> Share

  35. CAHILL EP
    Adding a COX-2 inhibitor improves efficacy of emergency contraception.
    Lancet. 2023 Aug 16:S0140-6736(23)01612-4. doi: 10.1016/S0140-6736(23)01612.
    >> Share

  36. LI RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, et al
    Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet. 2023 Aug 16:S0140-6736(23)01240-0. doi: 10.1016/S0140-6736(23)01240.
    >> Share

    July 2023
  37. DASGUPTA N, Ajazi EM, Schwartz TA, Marshall SW, et al
    Misclassification of overdose events in the X:BOT study.
    Lancet. 2023 Jul 19:S0140-6736(23)00113-7. doi: 10.1016/S0140-6736(23)00113.
    >> Share

  38. SABBAH N, Demar M, Sogbo F, Zappa M, et al
    Recurrent vomiting and confusion in pregnancy: hypercalcaemia due to parathyroid adenoma.
    Lancet. 2023;402:62-63.
    >> Share

  39. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    >> Share

    June 2023
  40. CLUVER CA, Walker SP
    Early delivery for pre-eclampsia might save lives in low-income and middle-income settings.
    Lancet. 2023 Jun 29:S0140-6736(23)00824-3. doi: 10.1016/S0140-6736(23)00824.
    >> Share

  41. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    >> Share

  42. LUCAS DN, Bamber JH, Quasim S
    Perinatal outcomes and the role of obstetric anaesthesia interventions.
    Lancet. 2023;401:2038-2039.
    >> Share

  43. QUENBY S, Booth K, Hiller L, Coomarasamy A, et al
    Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
    Lancet. 2023 Jun 1:S0140-6736(23)00693-1. doi: 10.1016/S0140-6736(23)00693.
    >> Share

    May 2023
  44. SHAHEEN-HUSSAIN S, Lombard A, Basile S
    Confronting medical colonialism and obstetric violence in Canada.
    Lancet. 2023;401:1763-1765.
    >> Share

  45. MCCURRY J
    Japan approves abortion pill.
    Lancet. 2023;401:1558.
    >> Share

  46. MOHIDDIN A, Semrau KEA, Simon J, Langlois EV, et al
    The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response.
    Lancet. 2023 May 5:S0140-6736(23)00721-3. doi: 10.1016/S0140-6736(23)00721.
    >> Share

    April 2023
  47. HEISLER M, Cox-Toure T, Kaufman R
    US abortion bans violate patients' right to information and to health.
    Lancet. 2023 Apr 24:S0140-6736(23)00808-5. doi: 10.1016/S0140-6736(23)00808.
    >> Share

  48. JAFFE S
    Drug developers caution against US mifepristone ban.
    Lancet. 2023;401:1325-1326.
    >> Share

  49. SHAND AW, Kidson-Gerber GL
    Anaemia in pregnancy: a major global health problem.
    Lancet. 2023 Apr 20:S0140-6736(23)00396-3. doi: 10.1016/S0140-6736(23)00396.
    >> Share

  50. PASRICHA SR, Mwangi MN, Moya E, Ataide R, et al
    Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00278-7. doi: 10.1016/S0140-6736(23)00278.
    >> Share

  51. CHANDYO RK, Kvestad I, Ulak M, Ranjitkar S, et al
    The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
    Lancet. 2023 Apr 6:S0140-6736(23)00346-X. doi: 10.1016/S0140-6736(23)00346.
    >> Share

    March 2023
  52. BERGH C, Lundin K
    No benefit to pregnancy or livebirth by time-lapse-based embryo selection in IVF.
    Lancet. 2023 Mar 30:S0140-6736(23)00219-2. doi: 10.1016/S0140-6736(23)00219.
    >> Share

  53. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
    Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
    >> Share

  54. PRAGUE JK
    Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
    Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
    >> Share

  55. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
    Lancet. 2023;401:856-857.
    >> Share

  56. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
    The need for appropriate language in the debate on medicalisation of pregnancy.
    Lancet. 2023;401:818-819.
    >> Share

  57. KAKURU A, Jagannathan P
    Can we reduce malaria in pregnancy and improve birth outcomes?
    Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
    >> Share

  58. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
    Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
    Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
    >> Share

  59. HAWKES S, Kedia S, Odunga S, Dahal M, et al
    From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
    Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
    >> Share

    February 2023
  60. MURRAY CJL
    A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
    Lancet. 2023;401:555-556.
    >> Share

  61. JACKSON A
    A systematic analysis points in the wrong direction for cervical cancer elimination.
    Lancet. 2023;401:555.
    >> Share

  62. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    >> Share

  63. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    >> Share

  64. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    >> Share

  65. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    >> Share

    January 2023
  66. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    >> Share

  67. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    >> Share

    December 2022
  68. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    >> Share

    November 2022
  69. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    >> Share

  70. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    >> Share

  71. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    >> Share

  72. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    >> Share

    October 2022
  73. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    >> Share

  74. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    >> Share

  75. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    >> Share

  76. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    >> Share

  77. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    >> Share

  78. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    >> Share

  79. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    >> Share

  80. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    >> Share

    September 2022
  81. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    >> Share

  82. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    >> Share

    August 2022
  83. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    >> Share

  84. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    >> Share

  85. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    >> Share

    July 2022
  86. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    >> Share

  87. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    >> Share

  88. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    >> Share

  89. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    >> Share

  90. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    >> Share

    June 2022
  91. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    >> Share

  92. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    >> Share

  93. SARASWAT L, Bhattacharya S
    Relugolix combination therapy for endometriosis pain.
    Lancet. 2022;399:2244-2245.
    >> Share

  94. HOLT E
    Poland to introduce controversial pregnancy register.
    Lancet. 2022;399:2256.
    >> Share

  95. THE LANCET
    Attitudes towards menopause: time for change.
    Lancet. 2022;399:2243.
    >> Share

  96. O'BRIEN E, Rich M
    Obstetric violence in historical perspective.
    Lancet. 2022;399:2183-2185.
    >> Share

  97. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
    Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
    Lancet. 2022;399:2103-2112.
    >> Share

  98. BARTZ D
    Incidence of perforation with intrauterine devices.
    Lancet. 2022;399:2076-2077.
    >> Share

    May 2022
  99. SCHAEDEL Z, Rymer J
    Menopause care and over the counter vaginal oestradiol.
    Lancet. 2022 May 31. pii: S0140-6736(22)00952.
    >> Share

  100. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
    Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
    Lancet. 2022;399:2014.
    >> Share

  101. RAVI K, Janiak E
    Adverse pregnancy outcomes: biological essentialism versus embodied biology.
    Lancet. 2022;399:2013-2014.
    >> Share

  102. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    >> Share

  103. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    >> Share

  104. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    >> Share

  105. JAFFE S
    Health organizations fear effects of US abortion ruling.
    Lancet. 2022;399:1854.
    >> Share

  106. VOSS FO, van Beurden M, Jordanova ES
    Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
    Lancet. 2022;399:1755-1757.
    >> Share

  107. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
    Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2022;399:1790-1798.
    >> Share

  108. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    >> Share

    April 2022
  109. MAKONI M
    Hope for access to abortion in Kenya.
    Lancet. 2022;399:1456.
    >> Share

  110. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    >> Share

    March 2022
  111. BOOTH A
    Activists welcome Colombia's decriminalisation of abortion.
    Lancet. 2022;399:899.
    >> Share

  112. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    >> Share

    February 2022
  113. PASHANKAR R, Prabulos AM, Feder HM Jr
    A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
    Lancet. 2022;399:e10.
    >> Share

  114. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    >> Share

  115. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
    Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Lancet. 2022;399:541-553.
    >> Share

  116. BLAGDEN SP
    Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Lancet. 2022;399:499-501.
    >> Share

  117. CERDEIRA AS, Ismail L, Moore N, George B, et al
    Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
    Lancet. 2022;399:554.
    >> Share

    January 2022
  118. HUG L, You D, Blencowe H, Moran AC, et al
    Strengthening the reporting of stillbirths globally - Authors' reply.
    Lancet. 2022;399:142.
    >> Share

  119. DAS AM, Janardhanan R
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:141.
    >> Share

  120. JOOS O, Swiney C, Sferrazza L
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:140-141.
    >> Share

    December 2021
  121. JAFFE S
    US Supreme Court expected to weaken abortion rights.
    Lancet. 2021;398:2137-2138.
    >> Share

    November 2021
  122. SANSON C, Majer M, Pautier P, Gouy S, et al
    Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
    Lancet. 2021;398:e17.
    >> Share

  123. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    >> Share

  124. CRUICKSHANK ME, Grigore M
    Cervical cancers avoided by HPV immunisation.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
    >> Share

  125. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
    Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
    Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
    >> Share

    October 2021
  126. THE LANCET
    Abortion bans in the USA harm health equity.
    Lancet. 2021;398:1461.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016